Harbour BioMed Receives the US FDA’s IND Clearance of HBM1020 for the Treatment of Advanced Solid Tumors
Shots:
- The US FDA has cleared an IND application to initiate the clinical trials evaluating the safety, tolerability, PK, and anti-tumor activity of HBM1020 in patients with advanced solid tumors
- Additionally, the preclinical study showed immune activation and anti-tumor functional activities. In PD-L1-/refractory patients, HBM1020 may offer patients a novel anti-tumor therapeutic that is complementary to PD-(L)1 therapies
- HBM1020 is a fully human mAb targeting B7H7 that has been developed from Harbour Mice H2L2 transgenic mice platform. By inhibiting the novel immune checkpoint target, the antibody can improve anti-tumor immunity
Ref: PR Newswire | Image: Harbour BioMed
Related News:- Harbour BioMed Signs Out-License Agreement with AstraZeneca for HBM7022 to Treat Solid Tumors Using HBICE Platform
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
